Gold(I) N-heterocyclic carbene complexes with an "activable" ester moiety: possible biological applications

[1]  A. Casini,et al.  A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. , 2014, Dalton transactions.

[2]  A. Casini,et al.  Emerging protein targets for metal-based pharmaceutical agents: an update , 2013 .

[3]  A. Casini,et al.  Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights. , 2013, Journal of medicinal chemistry.

[4]  M. Laguna,et al.  S-Propargylthiopyridine Phosphane Derivatives As Anticancer Agents: Characterization and Antitumor Activity , 2013 .

[5]  R. Rubbiani,et al.  TrxR inhibition and antiproliferative activities of structurally diverse gold N-heterocyclic carbene complexes , 2013 .

[6]  R. Rubbiani,et al.  N-Heterocyclic carbene metal complexes in medicinal chemistry. , 2013, Dalton transactions.

[7]  R. Gust,et al.  Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. , 2013, Chemical Society reviews.

[8]  R. Gust,et al.  Synthesis, characterization, and in vitro studies of bis[1,3-diethyl-4,5-diarylimidazol-2-ylidene]gold(I/III) complexes. , 2012, Journal of medicinal chemistry.

[9]  A. Casini,et al.  Next-generation anticancer metallodrugs. , 2012, Current topics in medicinal chemistry.

[10]  A. Gautier,et al.  Advances in metal-carbene complexes as potent anti-cancer agents. , 2012, Metallomics : integrated biometal science.

[11]  R. Gust,et al.  NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents. , 2011, Journal of medicinal chemistry.

[12]  A. Casini,et al.  Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. , 2011, Metallomics : integrated biometal science.

[13]  S. Wölfl,et al.  Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. , 2011, Journal of medicinal chemistry.

[14]  A. Casini,et al.  Multinuclear cytotoxic metallodrugs: physicochemical characterization and biological properties of novel heteronuclear gold-titanium complexes. , 2011, Inorganic chemistry.

[15]  G. Gasser,et al.  Organometallic Anticancer Compounds , 2010, Journal of medicinal chemistry.

[16]  F. Pelletier,et al.  Development of bimetallic titanocene-ruthenium-arene complexes as anticancer agents: relationships between structural and biological properties. , 2010, Journal of medicinal chemistry.

[17]  A. Casini,et al.  Antiproliferative Activity of Gold(I) Alkyne Complexes Containing Water-Soluble Phosphane Ligands , 2010 .

[18]  A. Casini,et al.  Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies , 2010, Medicinal research reviews.

[19]  I. Ott.  On the medicinal chemistry of gold complexes as anticancer drugs , 2009 .

[20]  A. Casini,et al.  Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs , 2009 .

[21]  Christian G Hartinger,et al.  Bioorganometallic chemistry--from teaching paradigms to medicinal applications. , 2009, Chemical Society reviews.

[22]  Anna F. A. Peacock,et al.  Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. , 2008, Chemistry, an Asian journal.

[23]  N. Metzler‐Nolte,et al.  The Synthesis of Ruthenium and Rhodium Complexes with Functionalized N‐Heterocyclic Carbenes and Their Use in Solid Phase Peptide Synthesis , 2008 .

[24]  H. Müller‐Bunz,et al.  Oxali‐Titanocene Y: A Potent Anticancer Drug , 2008, ChemMedChem.

[25]  G. Sheldrick.  A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[26]  E. Tiekink.  Anti-cancer potential of gold complexes , 2008, Inflammopharmacology.

[27]  A. Laguna,et al.  Tetrahydrothiophene)Gold(I) or Gold(III) Complexes , 2007 .

[28]  A. Vessières,et al.  Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects. , 2006, Dalton transactions.

[29]  I. J. Lin,et al.  Review of gold(I) N-heterocyclic carbenes , 2005 .

[30]  N. Farrell,et al.  Platinum coordination compounds in cancer chemotherapy , 2005 .

[31]  S. Berners‐Price,et al.  Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents. , 2004, Journal of inorganic biochemistry.

[32]  I. S. Kim,et al.  Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro , 2004, British journal of pharmacology.

[33]  N. Farrell.  Polynuclear platinum drugs. , 2004, Metal ions in biological systems.

[34]  Stephen J Lippard,et al.  Cisplatin and related anticancer drugs: recent advances and insights. , 2004, Metal ions in biological systems.

[35]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[36]  Maria Cristina Burla,et al.  SIR97: a new tool for crystal structure determination and refinement , 1999 .

[37]  Harrison M. J. Wang,et al.  FACILE SYNTHESIS OF SILVER(I)-CARBENE COMPLEXES. USEFUL CARBENE TRANSFER AGENTS , 1998 .